Personnel is not driving spending growth in the US FDA's biosimilar user fee program.
From fiscal year 2015 through FY 2017, spending on non-personnel items have more than doubled. And while personnel spending also...
Biosimilars At US FDA: Personnel Spending Losing Influence Over Program
Listen to this article
Percentage of personnel spending as a proportion of biosimilar review costs dropped more than 17% over three-year period as equipment and other spending more than doubled.
Learn what's happening at the US FDA. On the go.
More from Biosimilars
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
- • By
The bispecific antibody is the latest example of a growing number of biologics receiving complete response letters related to third-party manufacturing facilities.
- • By
A US FDA analysis found that facility inspection issues were the fastest growing factor in the recent rise of complete response letters for biologics licensing applications, in part reflecting the limitations of single-product inspections at contract facilities manufacturing multiple products.
- • By
A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.
More from Biosimilars & Generics
- • By
A US FDA analysis found that facility inspection issues were the fastest growing factor in the recent rise of complete response letters for biologics licensing applications, in part reflecting the limitations of single-product inspections at contract facilities manufacturing multiple products.
- • By
Novartis continues to fight tooth and nail to protect its $3bn Entresto brand in the US following the latest FDA approval of a generic version.
- • By
A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.
